Cargando…
How I treat my inflammatory bowel disease-patients with thiopurines?
Thiopurines are essential drugs to maintain remission in patients with inflammatory bowel disease (IBD). Thiopurines used in IBD are azathioprine (2.0-2.5 mg/kg), mercaptopurine (1.0-1.5 mg/kg) and thioguanine (0.2-0.3 mg/kg). However, mainly due to numerous adverse events associated with thiopurine...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095571/ https://www.ncbi.nlm.nih.gov/pubmed/27867685 http://dx.doi.org/10.4292/wjgpt.v7.i4.524 |
_version_ | 1782465305286541312 |
---|---|
author | Meijer, Berrie Mulder, Chris JJ van Bodegraven, Adriaan A de Boer, Nanne K H |
author_facet | Meijer, Berrie Mulder, Chris JJ van Bodegraven, Adriaan A de Boer, Nanne K H |
author_sort | Meijer, Berrie |
collection | PubMed |
description | Thiopurines are essential drugs to maintain remission in patients with inflammatory bowel disease (IBD). Thiopurines used in IBD are azathioprine (2.0-2.5 mg/kg), mercaptopurine (1.0-1.5 mg/kg) and thioguanine (0.2-0.3 mg/kg). However, mainly due to numerous adverse events associated with thiopurine use, almost 50% of the patients have to discontinue conventional thiopurine treatment. Extensive monitoring and the application of several treatment strategies, such as split-dose administration, co-administration with allopurinol or dose reduction/increase, may increase the chance of successful therapy. With this review, we provide practical information on how thiopurines are initiated and maintained in two thiopurine research centers in The Netherlands. We provide clinical information concerning safety issues, indications and management of therapy that may serve as a guide for the administration of thiopurines in IBD patients in daily practice. |
format | Online Article Text |
id | pubmed-5095571 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-50955712016-11-19 How I treat my inflammatory bowel disease-patients with thiopurines? Meijer, Berrie Mulder, Chris JJ van Bodegraven, Adriaan A de Boer, Nanne K H World J Gastrointest Pharmacol Ther Minireviews Thiopurines are essential drugs to maintain remission in patients with inflammatory bowel disease (IBD). Thiopurines used in IBD are azathioprine (2.0-2.5 mg/kg), mercaptopurine (1.0-1.5 mg/kg) and thioguanine (0.2-0.3 mg/kg). However, mainly due to numerous adverse events associated with thiopurine use, almost 50% of the patients have to discontinue conventional thiopurine treatment. Extensive monitoring and the application of several treatment strategies, such as split-dose administration, co-administration with allopurinol or dose reduction/increase, may increase the chance of successful therapy. With this review, we provide practical information on how thiopurines are initiated and maintained in two thiopurine research centers in The Netherlands. We provide clinical information concerning safety issues, indications and management of therapy that may serve as a guide for the administration of thiopurines in IBD patients in daily practice. Baishideng Publishing Group Inc 2016-11-06 2016-11-06 /pmc/articles/PMC5095571/ /pubmed/27867685 http://dx.doi.org/10.4292/wjgpt.v7.i4.524 Text en ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Minireviews Meijer, Berrie Mulder, Chris JJ van Bodegraven, Adriaan A de Boer, Nanne K H How I treat my inflammatory bowel disease-patients with thiopurines? |
title | How I treat my inflammatory bowel disease-patients with thiopurines? |
title_full | How I treat my inflammatory bowel disease-patients with thiopurines? |
title_fullStr | How I treat my inflammatory bowel disease-patients with thiopurines? |
title_full_unstemmed | How I treat my inflammatory bowel disease-patients with thiopurines? |
title_short | How I treat my inflammatory bowel disease-patients with thiopurines? |
title_sort | how i treat my inflammatory bowel disease-patients with thiopurines? |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095571/ https://www.ncbi.nlm.nih.gov/pubmed/27867685 http://dx.doi.org/10.4292/wjgpt.v7.i4.524 |
work_keys_str_mv | AT meijerberrie howitreatmyinflammatoryboweldiseasepatientswiththiopurines AT mulderchrisjj howitreatmyinflammatoryboweldiseasepatientswiththiopurines AT vanbodegravenadriaana howitreatmyinflammatoryboweldiseasepatientswiththiopurines AT deboernannekh howitreatmyinflammatoryboweldiseasepatientswiththiopurines |